Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2025 Results Exagen (NASDAQ: XGN) reported record 2025 results with $66.6M total revenue, a 20% increase, and AVISE CTD test volume growth of >11%. Trailing-twelve-month ASP rose to $441 (+7%). Company ended 2025 with $32.4M cash and raised capital via a $20M public offering and $25M credit facility.Net loss was $19.95M for the year; 2026 revenue guidance is $70M–$73M.

#XGN Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2025 Results

www.stocktitan.net/news/XGN/exagen-inc-repo...

Trade Alerts, Tuesday January 13, 2026 – Crystal Equity Research

Small-cap stocks with declining money flow, Tue Jan 13th - #XGN #TLRY #TCRT #SEVN #RSVR #PEBO #OMEX #MCBS #JAMF #IBCP #HYFM #GLRE #EHTH #DVLT #CCSI #BLFY #AFCG #ODV #EQBK #BOW - More: crystalequityresearch.com/trade-alerts... - #smallcap

Exagen Inc. Announces Select Preliminary 2025 Financial Results Exagen (Nasdaq: XGN) reported select preliminary unaudited results for the quarter and year ended December 31, 2025, consistent with prior guidance. Full-year revenue is projected at $66M–$67M, a 19%–20% increase versus 2024, and Q4 revenue is projected at $16M–$17M (up 17%–24%). The AVISE CTD test volume is 136,000–137,000 (TTM) with an ASP of $441–$445, an increase of at least $30 versus 2024. Year-end cash and cash equivalents were $32M, a $10M increase versus 2024. Results are preliminary and unaudited.

#XGN Exagen Inc. Announces Select Preliminary 2025 Financial Results

www.stocktitan.net/news/XGN/exagen-inc-anno...

Exagen Inc. Reports Strong Q3 2025 Results Exagen (Nasdaq: XGN) reported Q3 2025 results: revenue $17.2M (up 38% year-over-year), gross margin 58.4%, and trailing-twelve-month ASP $441 (up $37 vs Q3 2024). The company ended Q3 with $35.7M cash and reduced adjusted EBITDA loss to $(1.9)M for the quarter. Exagen commercially launched seronegative RA anti-PAD4 markers and presented research at ACR. The company reiterated full-year 2025 revenue guidance of $65M–$70M and said it could reach positive adjusted EBITDA in Q4 at the high end of that range.

#XGN Exagen Inc. Reports Strong Q3 2025 Results

www.stocktitan.net/news/XGN/exagen-inc-repo...

Exagen Announces Acceptance of Six Abstracts at 2025 American College of Rheumatology Convergence Exagen (Nasdaq: XGN) announced acceptance of six abstracts for ACR Convergence 2025, held Oct 24–29, 2025 in Chicago. The program includes a plenary presentation on Oct 27 highlighting a urinary tenascin C panel that may predict kidney function loss in lupus nephritis and several posters on anti-RA33, anti-PAD4, T cell biomarkers, a kidney-specific four-protein index, and a multianalyte lupus risk score to improve AVISE CTD diagnostic precision.Exagen will host an Innovation Theater on Oct 27, 2:30–3:15pm CDT and staff the booth #1228 for follow-up.

#XGN Exagen Announces Acceptance of Six Abstracts at 2025 American College of Rheumatology Convergence

www.stocktitan.net/news/XGN/exagen-announce...

Exagen Earnings: Record Q2 Revenue Signals Path to Profitability with 14% Growth and Expanded Test Volume Exagen reports record quarterly revenue, expands test volume 14%, and projects positive EBITDA by Q4. New executive appointments strengthen leadership. See full results.

#XGN Exagen Inc. Reports Strong Q2 2025 Results

www.stocktitan.net/news/XGN/exagen-inc-repo...

Michael Mahler, PhD Joins Exagen as Chief Scientific Officer to Enhance Leadership in Autoimmune Diagnostics Exagen (XGN) has appointed Dr. Michael Mahler as Chief Scientific Officer to enhance its autoimmune diagnostics leadership. Dr. Mahler, who earned his Ph.D. from the University of Heidelberg, brings over 20 years of experience in immunology and autoimmune research. His impressive background includes collaboration with autoimmune research pioneers at the Scripps Research Institute and previous role as Senior VP of Research Development at Werfen. With over 300 peer-reviewed publications and multiple patents, Dr. Mahler's expertise in autoantigen discovery and diagnostic innovation will drive Exagen's strategic initiatives in precision diagnostics for autoimmune diseases.

#XGN Michael Mahler, PhD Joins Exagen as Chief Scientific Officer to Enhance Leadership in Autoimmune Diagnostics

www.stocktitan.net/news/XGN/michael-mahler-...

Exagen Inc. Prices Public Offering of Common Stock Exagen Inc. (XGN) has announced the pricing of its public offering of 3,350,000 shares of common stock at $5.25 per share. The offering is expected to generate gross proceeds of $17.6 million before deducting underwriting discounts and expenses. The company has granted underwriters a 30-day option to purchase up to an additional 502,500 shares under the same terms.The offering, scheduled to close on May 9, 2025, is being conducted through Canaccord Genuity as the sole bookrunner. The public offering is made pursuant to a shelf registration statement on Form S-3 that was declared effective by the SEC on November 29, 2023.

#XGN Exagen Inc. Prices Public Offering of Common Stock

www.stocktitan.net/news/XGN/exagen-inc-pric...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with strong volume gains, Wed May 7th - #ZKIN #SKIN #RITR #PRCH #NRDS #LTRN #KE #IVVD #EOSE #EHTH #XGN #TROO #CHR #ATOM #OSCR #TPB #TIC #IHS #FTK #BALY - More: crystalequityresearch.com/SmCpStr/ - #smallcap

Exagen Inc. Announces Proposed Public Offering of Common Stock Exagen Inc. (XGN), an autoimmune testing solutions provider, has announced a proposed public offering of common stock. The company plans to grant underwriters a 30-day option to purchase up to an additional 15% of the offered shares. Canaccord Genuity will serve as the sole bookrunner for the offering. The offering will be conducted through a shelf registration statement on Form S-3 that was filed with the SEC on November 17, 2023, and declared effective on November 29, 2023. The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC.

#XGN Exagen Inc. Announces Proposed Public Offering of Common Stock

www.stocktitan.net/news/XGN/exagen-inc-anno...

Exagen Q1 Earnings: Record $15.5M Revenue as New Lupus Test Launch Sparks Growth Path to Profitability Exagen achieves $15.5M revenue milestone, expands test pricing by $42. See how new SLE biomarkers and $25M facility fuel path to positive EBITDA. Get Analysis

#XGN Exagen Inc. Reports Record Q1 2025 Revenue Driven by Growth in Average Selling Price and Testing Volume

www.stocktitan.net/news/XGN/exagen-inc-repo...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with strong volume gains, Tue Apr 1st - #XGN #TCRT #SASR #PCSA #NESR #MVST #HEPA #EXPW #DADA #CMLS #KNOP #FMBS #CLBR - More: crystalequityresearch.com/SmCpStr/ - #smallcap

Exagen Hits Major Milestones: Record Revenue, 1M Tests, and 62% Margins in Q4 Results Exagen delivers record-breaking performance with expanded margins, milestone of 1M AVISE tests, and increased test pricing. Company projects positive EBITDA by Q4 2025.

#XGN Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2024 Results and Business Highlights

www.stocktitan.net/news/XGN/exagen-inc-repo...

When Will Exagen Report Q4 Earnings? Key Date for Autoimmune Testing Investors Exagen will release Q4 and 2024 results before market open on March 11, followed by an 8:30 AM ET conference call with CEO John Aballi and CFO Jeff Black.

#XGN Exagen Inc. to Announce Fourth Quarter and Full-Year 2024 Financial Results on March 11, 2025

www.stocktitan.net/news/XGN/exagen-inc-to-a...

NEWS: ( NASDAQ: #XGN ) Exagen Inc. to Participate in Upcoming Investor Conferences

JUST IN: ( NASDAQ: #XGN ) Exagen Inc. Secures Conditional NY State Approval for New Lupus and Rheumatoid Arthritis Biomarkers and Announces Select Preliminary 2024 Financial Results

Exagen Achieves Record $55.8M Revenue, Gets NY Approval for New Lupus & RA Biomarker Tests Exagen secures conditional NY approval for innovative lupus and RA biomarker assays, reports record 2024 revenue and reaches 1 million AVISE CTD test milestone.

#XGN Exagen Inc. Secures Conditional NY State Approval for New Lupus and Rheumatoid Arthritis Biomarkers and Announces Select Preliminary 2024 Financial Results

www.stocktitan.net/news/XGN/exagen-inc-secu...

Need to start posting here more. Algorithm, bring me friends

#BisexualGamer #PolyamorousGamer #GamingWithPride #HorrorGaming #PokemonFan #SpookyVibes #GottaCatchEmAll #WomenInGaming #QueerGamers #StreamerLife #CreepyAndCute #GirlGamersUnite #XGN

Breaking News: ( NASDAQ: #XGN ) Exagen Inc. Achieves Key Milestone with 1,000,000th Patient Tested by AVISE CTD

#StockMarket #News

Exagen Hits Major Milestone: 1 Million AVISE Tests Revolutionize Autoimmune Disease Diagnosis Exagen's AVISE CTD diagnostic test achieves 1M test milestone, marking significant advancement in autoimmune disease detection with superior accuracy over traditional methods.

#XGN Exagen Inc. Achieves Key Milestone with 1,000,000th Patient Tested by AVISE® CTD

#StockMarket #investing #news

www.stocktitan.net/news/XGN/exagen-inc-achi...

#XGN Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD Platform

www.stocktitan.net/news/XGN/exagen-inc-comp...

#XGN Exagen Inc. to Participate in Fourth Quarter Investor Conferences

www.stocktitan.net/news/XGN/exagen-inc-to-p...

JUST IN: ( NASDAQ: #XGN ) Exagen Inc. Reports Strong Second Quarter 2024 Results: Raises Guidance due to Record Performance

#StockMarket #News

Breaking News: ( NASDAQ: #XGN ) Exagen Inc. to Participate in the Canaccord Genuity 44th Annual Growth Conference

#StockMarket #News

Madre del amor hermoso. Vaya fin de semana de #xgn. Ha sido un placer volver a juntarme con gente tan maja